Scorpion completes drilling at Pharos lithium project just in time for Xmas
Scorpion Minerals has wrapped up maiden drilling at the Pharos lithium project in WA Historical sampling previously returned up to 2.99% LI2O Assays are expected [more…]
Raiden eyes mouthwatering walk-up drilling with five extra target zones to sink into at Andover South
Raiden has defined five more target zones for a maiden drill program at Andover South Soil sampling and shallow drilling to be undertaken in tandem [more…]
The Rollercoaster Year: The Financial Market’s Journey Through 2023
As 2023 draws to a close, we reflect on a tumultuous yet remarkable period in the financial markets. This year has been nothing short of [more…]
Biden’s Judicial Appointment Race Against Time as 2024 Elections Approach
As the United States braces for the 2024 elections, President Joe Biden faces a crucial period in shaping the judicial landscape, contending with the prolific [more…]
Confessions of a Day Trader: Thanks WiseTech – we’re putting in a pool!
Each week, Stockhead’s resident day trader gives us a peek at the highs and lows of his trading diary and hints at what might be [more…]
Guy on Rocks: Uranium boom in ’24? We’ll smoke to that…
‘Guy on Rocks’ is a Stockhead series looking at the significant happenings of the resources market each week. Former geologist and experienced stockbroker Guy Le [more…]
Dr Boreham’s End-of-Year ASX Biotech report card
If the biotech sector were a classroom, the teacher’s end-of-year report card would read something like: “a patchy but solid effort in trying conditions, with [more…]
Emission Control: Will nuclear energy have a place in Australia’s grid future?
A new report by CSIRO and AEMO has found that new build costs for electric generation, energy storage and hydrogen production in Australia have stabilised [more…]
Hot Money Monday: Adbri and Comet Ridge have all the momentum right now
Momentum investing works on the theory that strong stocks will continue to rise in price, while weak stocks will continue to decline. On the up [more…]
Part 1: ASX biotechs with catalysts looking to pop in 2024
Neuren set to uphold momentum in 2024 as front-runner among biotechs with catalysts next year Dimerix’s first analysis outcome for its Phase 3 trial of [more…]
